Development of N-2,4-pyrimidine-N-phenyl-N′-phenyl ureas as inhibitors of tumor necrosis factor alpha (TNF-α) synthesis.: Part 1

被引：17

作者：

Brugel, Todd A. ^{[1
]}

Maier, Jennifer A. ^{[1
]}

Clark, Michael P. ^{[1
]}

Sabat, Clark Mark ^{[1
]}

Goleblowski, Adam ^{[1
]}

Bookland, Roger G. ^{[1
]}

Laufersweiler, Matthew J. ^{[1
]}

Laughlin, Steven K. ^{[1
]}

VanRens, John C. ^{[1
]}

De, Biswanath ^{[1
]}

Hsieh, Lily C. ^{[1
]}

Mekel, Marlene J. ^{[1
]}

Janusz, Michael J. ^{[1
]}

机构：

[1] Procter & Gamble Pharmaceut, Hlth Care Res Ctr, Mason, OH 45040 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2006年 / 16卷 / 13期

关键词：

cytokine synthesis inhibitors; p38 alpha kinase; urea;

D O I：

10.1016/j.bmcl.2006.03.095

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A new class of tumor necrosis factor alpha (TNF-alpha) synthesis inhibitors based on an N-2,4-pyrimidine-N-phenyl-N'-phenyl urea scaffold is described. Many of these compounds showed low-nanomolar activity against lipopolysaccharide stimulated TNF-alpha production. X-ray co-crystallization studies with mutated p38 alpha showed that these trisubstituted ureas interact with the ATP-binding pocket in a pseudo-bicyclic conformation brought about by the presence of an intramolecular hydrogen bonding interaction. (c) 2006 Elsevier Ltd. All rights reserved.

引用

页码：3510 / 3513

页数：4

共 13 条

[1]

Adams JL, 2001, PROGR MED CHEM, V38, P1, DOI 10.1016/S0079-6468(08)70091-2

[2]

Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453

[3] 5-(3-CARBOXYMETHOXYPHENYL)-2-(4,5-DIMETHYLTHIAZOLYL)-3-(4-SULFOPHENYL)TETRAZOLIUM, INNER SALT (MTS) AND RELATED ANALOGS OF 3-(4,5-DIMETHYLTHIAZOLYL)-2,5-DIPHENYLTETRAZOLIUM BROMIDE (MTT) REDUCING TO PURPLE WATER-SOLUBLE FORMAZANS AS CELL-VIABILITY INDICATORS [J].

BARLTROP, JA ;

OWEN, TC ;

CORY, AH ;

CORY, JG .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1991, 1 (11) :611-&

[4] New inhibitors of p38 kinase [J].

Boehm, JC ;

Adams, JL .

EXPERT OPINION ON THERAPEUTIC PATENTS, 2000, 10 (01) :25-37

[5] Structure-activity relationships of p38 mitogen-activated protein kinase inhibitors [J].

Bolós, J .

MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2005, 5 (09) :857-868

[6] Development of orally bioavailable bicyclic pyrazolones as inhibitors of tumor necrosis factor-α production [J].

Clark, MP ;

Laughlin, SK ;

Laufersweiler, MJ ;

Bookland, RG ;

Brugel, TA ;

Golebiowski, A ;

Sabat, MP ;

Townes, JA ;

VanRens, JC ;

Djung, JF ;

Natchus, MG ;

De, B ;

Hsieh, LC ;

Xu, SC ;

Walter, RL ;

Mekel, MJ ;

Heitmeyer, SA ;

Brown, KK ;

Juergens, K ;

Taiwo, YO ;

Janusz, MJ .

JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (11) :2724-2727

[7] Pathway to the clinic: Inhibition of p38 MAP kinase. A review of ten chemotypes selected for development [J].

Goldstein, DM ;

Gabriel, T .

CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2005, 5 (10) :1017-1029

[8] A MAP KINASE TARGETED BY ENDOTOXIN AND HYPEROSMOLARITY IN MAMMALIAN-CELLS [J].

HAN, J ;

LEE, JD ;

BIBBS, L ;

ULEVITCH, RJ .

SCIENCE, 1994, 265 (5173) :808-811

[9] MAP kinase p38 inhibitors:: Clinical results and an intimate look at their interactions with p38α protein [J].

Lee, MR ;

Dominguez, C .

CURRENT MEDICINAL CHEMISTRY, 2005, 12 (25) :2979-2994

[10] PROTECTION AGAINST A LETHAL DOSE OF ENDOTOXIN BY AN INHIBITOR OF TUMOR-NECROSIS-FACTOR PROCESSING [J].

MOHLER, KM ;

SLEATH, PR ;

FITZNER, JN ;

CERRETTI, DP ;

ALDERSON, M ;

KERWAR, SS ;

TORRANCE, DS ;

OTTENEVANS, C ;

GREENSTREET, T ;

WEERAWARNA, K ;

KRONHEIM, SR ;

PETERSEN, M ;

GERHART, M ;

KOZLOSKY, CJ ;

MARCH, CJ ;

BLACK, RA .

NATURE, 1994, 370 (6486) :218-220

← 1 2 →